Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Recent NewsMore >>
DateTitle 
04/30/15Geron Corporation Reports First Quarter 2015 Financial Results and Recent EventsPrinter Friendly Version
04/27/15Geron to Present at the Bank of America Merrill Lynch Healthcare ConferencePrinter Friendly Version
04/07/15Geron to Present at the 14th Annual Needham Healthcare ConferencePrinter Friendly Version
Upcoming EventsMore >>
To be announced.
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$4.15
Change (%) Stock is Down 0.25 (5.68%)
Volume2,437,569
Data as of 07/02/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
  
Contact Information

Olivia Bloom
Tel: 650-473-7700
E-mail: investor@geron.com or media@geron.com



RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | Financial Tear Sheet Financial Tear Sheet
Close
Form content here please :)